Literature DB >> 21412376

Breakthrough pain in chronic non-cancer pain: fact, fiction, or abuse.

Laxmaiah Manchikanti1, Vijay Singh, David L Caraway, Ramsin M Benyamin.   

Abstract

Treatment of chronic non-cancer pain with opioid therapy has escalated in recent years, resulting in exploding therapeutic use and misuse of prescription opioids and multiple adverse drug events. Breakthrough pain is defined as a transient exacerbation of pain experienced by individuals who have relatively stable and adequately controlled baseline cancer pain. Further, the definition of breakthrough pain, prevalence, characteristics, implications, and treatment modalities have been extensively described for chronic cancer pain. However, the literature for breakthrough pain in chronic non-cancer pain including its terminology, prevalence, relevance, characteristics, and treatments, have been poorly described and continue to be debated. The philosophy of breakthrough pain in chronic non-cancer pain raises multiple issues leading almost all patients to be on high dose long-acting opioids, followed by supplementing with short-acting drugs, instead of treating the patients with only short-acting drugs as required. Consequently, the subject of breakthrough pain in chronic non-cancer pain is looked at with suspicion due to the lack of evidence and inherent bias associated with its evaluation, followed by escalating use and abuse of opioids. Multiple issues related to the concept of breakthrough pain in chronic non-cancer pain evolve around extensive use, overuse, misuse, and abuse of opioids. In the era of eliminating opioids or significantly curtailing their use to only appropriate indications, the concept of breakthrough pain raises multiple questions without any scientific evidence. This review illustrates that there is no significant evidence for any type of breakthrough pain in chronic non-cancer pain based on available literature, methodology utilized, and response to opioids in chronic non-cancer pain. The advocacy for increased usage of opioids in the treatment of chronic pain dates back to the liberalization of laws governing opioid prescription for the treatment of chronic non-cancer pain by state medical boards in the late 1990s, and is exploding with new pain management standards for inpatient and outpatient medical care implemented by the Joint Commission on Accreditation of Health Care Organizations in 2000, and the advocacy by many physicians and organizations for increased use of opioids. This comprehensive review critically evaluates the available evidence of breakthrough pain in chronic non-cancer pain including its existence, prevalence, and managing symptoms which are described as breakthrough pain or episodic pain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412376

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  13 in total

1.  Peripheral nerve stimulation for trigeminal neuropathic pain.

Authors:  David A Stidd; Adam L Wuollet; Kirk Bowden; Theodore Price; Amol Patwardhan; Steve Barker; Martin E Weinand; Jeffrey Annabi; Emil Annabi
Journal:  Pain Physician       Date:  2012 Jan-Feb       Impact factor: 4.965

Review 2.  Management of pain with comorbid substance abuse.

Authors:  Daniel Krashin; Natalia Murinova; Jane Ballantyne
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

3.  Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.

Authors:  Jordi Guitart; Isabel Vargas; Vicente De Sanctis; Julia Ferreras; Jose Fuentes; Rafael Salazar; Juan M Vázquez; Jordi Folch; Jordi Moya; Hermann Ribera; Francisco Rodelas; Albert Tomás; María Arilla; Joan Coma; Teresa Aberasturi; Dolores Sintes; Ester Lombán
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

Review 4.  Fentanyl for the treatment of tumor-related breakthrough pain.

Authors:  Helmar Bornemann-Cimenti; Mischa Wejbora; Istvan S Szilagyi; Andreas Sandner-Kiesling
Journal:  Dtsch Arztebl Int       Date:  2013-04-19       Impact factor: 5.594

Review 5.  [Breakthrough pain and short-acting opioids].

Authors:  T Beutlhauser; J Oeltjenbruns; M Schäfer
Journal:  Anaesthesist       Date:  2013-06       Impact factor: 1.041

6.  Opioid rotation with extended-release opioids: where should we begin?

Authors:  Srinivas Nalamachu
Journal:  Int J Gen Med       Date:  2011-12-30

7.  An evaluation of total disintegration time for three different doses of sublingual fentanyl tablets in patients with breakthrough pain.

Authors:  Srinivas Nalamachu
Journal:  Pain Ther       Date:  2013-11-19

8.  Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study.

Authors:  J Boceta; A De la Torre; D Samper; M Farto; R Sánchez-de la Rosa
Journal:  Clin Transl Oncol       Date:  2016-11       Impact factor: 3.405

9.  The effect of transdermal opioid use on breakthrough opioid and sedative prescribing for rural patients with chronic pain in Northwest Tasmania: a longitudinal study.

Authors:  John Henshaw; Judi Walker; Dom Geraghty
Journal:  J Pain Res       Date:  2013-04-17       Impact factor: 3.133

10.  Hearing new voices: registered nurses and health technicians experience caring for chronic pain patients in primary care clinics.

Authors:  Linda H Pellico; Wesley P Gilliam; Allison W Lee; Robert D Kerns
Journal:  Open Nurs J       Date:  2014-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.